ID

33443

Description

Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression; ODM derived from: https://clinicaltrials.gov/show/NCT02431169

Lien

https://clinicaltrials.gov/show/NCT02431169

Mots-clés

Versions (1)
  1. 09/12/2018 09/12/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

9 décembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Carcinoma, Non-Small-Cell-Lung NCT02431169

Anglais

Eligibility Carcinoma, Non-Small-Cell-Lung NCT02431169

1 Formulaires  
Criteria
Description

Criteria

diagnosis of metastatic stage iiib/iv lung adenocarcinoma
Description

LUNG CANCER ADENOCARCINOMA METASTATIC TNM clinical staging

Type de données

boolean

Alias
UMLS CUI [1,1]
C0746071
UMLS CUI [1,2]
C3258246
presence of known sensitizing mutations in egfr tk domain (exon 19 deletion and l858r)
Description

Epidermal Growth Factor Receptor Mutation | EGFR exon 19 deletion | EGFR Exon 21 L858R Mutation

Type de données

boolean

Alias
UMLS CUI [1,1]
C0034802
UMLS CUI [1,2]
C0026882
UMLS CUI [2]
C3889117
UMLS CUI [3]
C3274204
absence of known resistant mutations in the egfr tk domain (t790m)
Description

Absence Epidermal Growth Factor Receptor Mutation Resistant | EGFR T790M

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0034802
UMLS CUI [1,3]
C0026882
UMLS CUI [1,4]
C0332325
UMLS CUI [2]
C3274192
consented to hrpo# 201305031 ("tissue and blood acquisition for genomic analysis and collection of health information from patients with thoracic malignancies, suspected thoracic malignancies, or mesothelioma")
Description

Consent Clinical Trial Specified

Type de données

boolean

Alias
UMLS CUI [1,1]
C1511481
UMLS CUI [1,2]
C0008976
UMLS CUI [1,3]
C0205369
up to one prior line of systemic treatment for this malignancy
Description

Systemic therapy Malignant Neoplasms

Type de données

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0006826
no prior localized therapy to the biopsy site
Description

Absence Localized Therapy Biopsy site

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C1517925
UMLS CUI [1,3]
C1301128
planned treatment with standard of care erlotinib
Description

Erlotinib Standard of Care Planned

Type de données

boolean

Alias
UMLS CUI [1,1]
C1135135
UMLS CUI [1,2]
C2936643
UMLS CUI [1,3]
C1301732
not pregnant or breastfeeding
Description

Pregnancy Absent | Breast Feeding Absent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0006147
UMLS CUI [2,2]
C0332197
at least 18 years of age
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
able to understand and willing to sign a written informed consent document
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Retour au début de la page

Similar models

Eligibility Carcinoma, Non-Small-Cell-Lung NCT02431169

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
LUNG CANCER ADENOCARCINOMA METASTATIC TNM clinical staging
Item
diagnosis of metastatic stage iiib/iv lung adenocarcinoma
boolean
C0746071 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Epidermal Growth Factor Receptor Mutation | EGFR exon 19 deletion | EGFR Exon 21 L858R Mutation
Item
presence of known sensitizing mutations in egfr tk domain (exon 19 deletion and l858r)
boolean
C0034802 (UMLS CUI [1,1])
C0026882 (UMLS CUI [1,2])
C3889117 (UMLS CUI [2])
C3274204 (UMLS CUI [3])
Absence Epidermal Growth Factor Receptor Mutation Resistant | EGFR T790M
Item
absence of known resistant mutations in the egfr tk domain (t790m)
boolean
C0332197 (UMLS CUI [1,1])
C0034802 (UMLS CUI [1,2])
C0026882 (UMLS CUI [1,3])
C0332325 (UMLS CUI [1,4])
C3274192 (UMLS CUI [2])
Consent Clinical Trial Specified
Item
consented to hrpo# 201305031 ("tissue and blood acquisition for genomic analysis and collection of health information from patients with thoracic malignancies, suspected thoracic malignancies, or mesothelioma")
boolean
C1511481 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C0205369 (UMLS CUI [1,3])
Systemic therapy Malignant Neoplasms
Item
up to one prior line of systemic treatment for this malignancy
boolean
C1515119 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
Absence Localized Therapy Biopsy site
Item
no prior localized therapy to the biopsy site
boolean
C0332197 (UMLS CUI [1,1])
C1517925 (UMLS CUI [1,2])
C1301128 (UMLS CUI [1,3])
Erlotinib Standard of Care Planned
Item
planned treatment with standard of care erlotinib
boolean
C1135135 (UMLS CUI [1,1])
C2936643 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
Pregnancy Absent | Breast Feeding Absent
Item
not pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Age
Item
at least 18 years of age
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
able to understand and willing to sign a written informed consent document
boolean
C0021430 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial